Syngene International Limited Stock Bombay S.E.

Equities

SYNGENE

INE398R01022

Biotechnology & Medical Research

Market Closed - Bombay S.E. 06:00:50 2024-04-26 am EDT 5-day change 1st Jan Change
698.2 INR -0.10% Intraday chart for Syngene International Limited -2.11% -0.41%
Sales 2024 34.89B 419M Sales 2025 * 39.52B 474M Capitalization 278B 3.34B
Net income 2024 5.1B 61.23M Net income 2025 * 5.72B 68.72M EV / Sales 2024 8 x
Net cash position 2024 * 8.29B 99.55M Net cash position 2025 * 9.1B 109M EV / Sales 2025 * 6.81 x
P/E ratio 2024
55.4 x
P/E ratio 2025 *
50.9 x
Employees 6,847
Yield 2024 *
0.19%
Yield 2025 *
0.21%
Free-Float 44.65%
More Fundamentals * Assessed data
Dynamic Chart
Jefferies Downgrades Syngene International to Underperform From Hold, Adjusts Price Target to INR620 From INR690 MT
Transcript : Syngene International Limited, Q4 2024 Earnings Call, Apr 25, 2024
Syngene International Limited Recommends Final Dividend for the Financial Year 2024 CI
Syngene International Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Syngene International Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
INDIA STOCKS-Financials drag Indian shares, hit by fading US rate cut hopes RE
Syngene Biologics Manufacturing Facility to Be Operational for U.S. and European Customers from Mid-Year CI
Bristol Myers CEO says India to have largest R&D presence outside US by 2025 RE
Jefferies Adjusts Syngene International’s Price Target to INR690 From INR770, Keeps at Hold MT
Syngene International Posts Gains in Fiscal Q3 Consolidated Net Profit MT
Transcript : Syngene International Limited, Q3 2024 Earnings Call, Jan 25, 2024
Syngene International Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Syngene International Limited Appoints Mr. Sibaji Biswas as Additional Director Designated as Executive Director, Effective on April 01, 2024 CI
Syngene International Completes Acquisition of Stelis Biopharma's Biologics Plant MT
Syngene International Limited completed the acquisition of Unit 3 biologics manufacturing facility in Bangalore from Stelis Biopharma Private Limited for INR 6.2 billion. CI
More news
1 day-0.10%
1 week-2.11%
Current month-0.49%
1 month-0.92%
3 months+2.22%
6 months+2.23%
Current year-0.41%
More quotes
1 week
668.85
Extreme 668.85
732.20
1 month
668.85
Extreme 668.85
767.75
Current year
660.35
Extreme 660.35
775.45
1 year
632.00
Extreme 632
860.20
3 years
508.10
Extreme 508.1
860.20
5 years
201.65
Extreme 201.65
860.20
10 years
147.50
Extreme 147.5
860.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 15-02-28
Director of Finance/CFO - 19-12-17
Chairman 71 94-11-17
Members of the board TitleAgeSince
Chairman 71 94-11-17
Director/Board Member 67 17-07-30
Chief Executive Officer 55 15-02-28
More insiders
Date Price Change Volume
24-04-26 698.2 -0.10% 29 097
24-04-25 699 +0.68% 109,155
24-04-24 694.2 -1.00% 23,317
24-04-23 701.2 -0.52% 12,092
24-04-22 704.8 -1.18% 9,397

Delayed Quote Bombay S.E., April 26, 2024 at 06:00 am EDT

More quotes
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
699.1 INR
Average target price
742.6 INR
Spread / Average Target
+6.23%
Consensus